Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Intermittent dosing of dasatinib with a once daily regimen has been shown to reduce side effects while preserving clinical efficacy in early and advanced phase chronic myeloid leukemia (CML). Yet, hematologic toxicity and fluid retention demand a dose modification or treatment discontinuation in selected patients. Patients resistant or intolerant to imatinib were retrospectively evaluated based on the toxicity-guided administration of a dose-reduced dasatinib regimen. Patients were treated with an on/off regimen (3 to 5 days on, 2 to 4 days off) to allow regression of dasatinib-dependent off-target toxicity. Patients were followed up by routine hematologic and cytogenetic assessment and molecular monitoring to safeguard clinical response to the altered drug schedule. Thirty-three CML patients primarily in chronic phase with imatinib intolerance (n = 11) or resistance (n = 22) were investigated. Nonexclusive reasons for dose reduction were hematologic toxicity (17/33, 51%) and pleural effusions (18/33, 55%). On/off treatment with a weekend drug holiday significantly reduced pleural effusions and hematologic toxicity. Eighteen of 31 (58%) patients showed effective disease control despite reduced total weekly dasatinib doses, either demonstrated by achieving an improved response level (12/31) or keeping the response level achieved by conventional continuous dosing (6/31). Of note, 10/12 patients with subsequently improved response have been treated for a minimum of 6 months with…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most potential side-effects of D can be avoided though intermittent administration and, generally, serious side effects of D reverse upon temporary discontinuation [62,63], increasing the value of the opportunity to administer D intermittently, yet still benefit from its senolytic effects.”
Citations
Cites
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“imatinib or the imatinib-derivative nilotinib [4, 5].”
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 1×
“Thus, the dogma fueled by murine models of CML that continuous target inhibition is a prerequisite for effective leukemic cell kill can no longer be upheld for dasatinib, which represents a different class of ABLtargeting inhibitors with reduced selectivity and enhanced potency [5, 22, 23].”
BackgroundDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 3×
“However, clinical results demonstrated equal disease control with reduced toxicity in patients treated with a once daily (QD) regimen (1×100 mg) [3].”
BackgroundDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589 · cited 1×
“Toxicity rates are higher in patients treated with second-line compared to first-line patients with the marked difference that patients in the secondline study had a median age of 59 vs 47 years in the first-line DASISION study [11, 12].”
ResultSelf-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291 · cited 2×
“Clinical response was assessed using the European LeukemiaNet criteria [14].”
BackgroundMethodSelf-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · cited 2×
“imatinib or the imatinib-derivative nilotinib [4, 5].”
BackgroundDruker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707 · cited 1×
“This suggested that a twice daily dosing (BID) regimen (2× 50 mg) would be necessary for continuous kinase inhibition, which was believed to be a dominant response-determining variable [7].”
BackgroundClinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665 · cited 1×
“Furthermore, dasatinib in comparison to imatinib, which has a plasma half-life of 19 h, has a significantly shortened plasma half-life of 3 to 5 h preventing patients from repetitive subtherapeutic drug levels that might promote the development of resistance [24, 25].”
BackgroundKantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610 · cited 2×
“The DASISION study group reported on the randomized first-line treatment of CML patients with dasatinib or imatinib [2].”
BackgroundSelf-citationHochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Self-citation
Cited by
Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383
“Most potential side-effects of D can be avoided though intermittent administration and, generally, serious side effects of D reverse upon temporary discontinuation [62,63], increasing the value of the opportunity to administer D intermittently, yet still benefit from its senolytic effects.”
BackgroundSteegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Self-citationPediatric chronic myeloid leukemia is a unique disease that requires a different approach
Hijiya, N., Schultz, K. R., Metzler, M., Millot, F., & Suttorp, M. (2016) · Blood · doi:10.1182/blood-2015-06-648667 · Cited by 214
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M. L., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0007 · Cited by 195
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
García-Gutiérrez, V., & Hernández-Boluda, J. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00603 · Cited by 134
Hughes, T. P., Laneuville, P., Rousselot, P. H., Snyder, D., Réa, D., Shah, N. P., Paar, D., Abruzzese, E., Hochhaus, A., Lipton, J. H., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188987 · Cited by 104
“Median (range) 41 (18-84) 56 (24-82) 53 (18-84) 60 (22-84)”
BackgroundSelf-citationLindauer, M., & Hochhaus, A. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_2 · Cited by 100
Self-citationLindauer, M., & Hochhaus, A. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_2 · Cited by 91
Self-citationSamis, J. H., Lee, P., Zimmerman, D., Arceci, R. J., Suttorp, M., & Hijiya, N. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26028 · Cited by 79
“Some studies indicate that intermittent dosing of TKIs may improve drug tolerability in adult patients who are suffering from side effects [75] while also maintaining a molecular response.”
BackgroundHochhaus, A., & Kantarjian, H. M. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1488-z · Cited by 85
Self-citationHallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics
Bulbiankova, D., Díaz‐Puertas, R., Álvarez‐Martínez, F. J., Herranz‐López, M., Barrajón‐Catalán, E., & Micol, V. (2023) · Antioxidants · doi:10.3390/antiox12020444 · Cited by 75
Chronic Myeloid Leukemia in Children
Hijiya, N., Millot, F., & Suttorp, M. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.008 · Cited by 77
Hjorth‐Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde‐Dahl, T., Gjertsen, B. T., Höglund, M., Koskenvesa, P., Lotfi, K., et al. (2015) · European Journal of Haematology · doi:10.1111/ejh.12423 · Cited by 63
Senolytics: Potential for Alleviating Diabetes and Its Complications
Palmer, A. K., Tchkonia, T., & Kirkland, J. L. (2021) · Endocrinology · doi:10.1210/endocr/bqab058 · Cited by 46
“In fact, an intermittent dosing schedule was shown to improve tolerability of D in patients with chronic myeloid leukemia (51).”
BackgroundManaging Pregnancy in Chronic Myeloid Leukaemia
Abruzzese, E., & Apperley, J. F. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-71913-5_14 · Cited by 51
Iurlo, A., Cattaneo, D., Bucelli, C., & Breccia, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030515 · Cited by 45
“As an alternative option, an “on/off” treatment schedule with a weekend drug holiday could also be considered [26].”
BackgroundIurlo, A., Galimberti, S., Abruzzese, E., Annunziata, M., Bonifacio, M., Latagliata, R., Pregno, P., Ferrero, D., Sorà, F., Orlandi, E. M., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3144-1 · Cited by 37
Hochhaus, A., Ernst, T., Eigendorff, E., & Rosée, P. G. L. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2323-1 · Cited by 37
Self-citationIs There a Role for Dose Modification of TKI Therapy in CML?
Copland, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00524-w · Cited by 36
Dasatinib dose management for the treatment of chronic myeloid leukemia
Talpaz, M., Saglio, G., Atallah, E., & Rousselot, P. (2018) · Cancer · doi:10.1002/cncr.31232 · Cited by 30
“Intermittent dosing with dasatinib has been shown to improve tolerability in patients with CML who were resistant to or intolerant of imatinib.(15) A strategy of 3 to 5 days of dasatinib, followed by 2 to 4 days of no drug, reduced toxicity while maintaining efficacy.”
BackgroundWaetzig, R., Matthes, M., Leister, J., Penkivech, G., Heise, T., Corbacioglu, S., & Sommer, G. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.48393 · Cited by 23
“The metronomic therapy is expected to reduce toxicity [10], prevent drug resistance, and to alter the tumor microenvironment in a more anti-tumorigenic manner [9].”
BackgroundTargeting multiple hallmarks of mammalian aging with combinations of interventions
Panchin, A. Y., Ogmen, A., Blagodatski, A. S., Egorova, A., Batin, M., & Glinin, T. S. (2024) · Aging · doi:10.18632/aging.206078 · Cited by 25
“Finally, such a regimen was shown to reduce the side effects of dasatinib [110, 111].”
BackgroundThe potential of Senolytics in transplantation
Matsunaga, T., Iske, J., Schroeter, A., Azuma, H., Zhou, H., & Tullius, S. G. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111582 · Cited by 22
Busque, L., Beaudet, M.-É., Harnois, M., Moussa, H., Szuber, N., Mollica, L. R., Delage, R., Olney, H. J., Laneuville, P., Cournoyer, G., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01242-8 · Cited by 23
Yates, J. W. T., Dudley, P., Cheng, J. J., D’Cruz, C. M., & Davies, B. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2795-7 · Cited by 17
“This concept has been exemplified preclinically by intermittent dosing schedules of the EGFR inhibitor gefitinib in combination with paclitaxel in NSCLC xenografts [9, 10], sorafenib in 786-0 RCC xenografts [11] and the Jak2 inhibitor MRLB11055 in mouse models of polycythemia vera [12], and in the clinic for gefitinib…”
BackgroundGu, Y., Avolio, E., Alvino, V. V., Thomas, A. C., Herman, A., Miller, P. J., Sullivan, N., Faulkner, A., & Madeddu, P. R. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01955-9 · Cited by 16
“We preferred to use intermittent treatment schedules to reduce potential toxic effects while preserving clinical efficacy [51].”
MethodAdverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
Yoshifuji, K., & Sasaki, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021662 · Cited by 15
“This regimen significantly reduced adverse events such as pleural effusion and hematologic toxicity, and 58% achieved disease control (72).”
BackgroundJamison, C., Nelson, D., Eren, M., Gauchan, D., Ramaekers, R. C., Norvell, M., & Copur, M. S. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504015x14452563485986 · Cited by 12
“In a retrospective analysis, alternate scheduling of low-dose dasatinib with weekend holidays has been shown to increase the compliance along with successful long-term disease control (13).”
BackgroundNuances to precision dosing strategies of targeted cancer medicines
Hopkins, A. M., Menz, B. D., Wiese, M. D., Kichenadasse, G., Gurney, H., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.625 · Cited by 12
Smith, B. D., Liu, J., Latrémouille-Viau, D., Guérin, A., Fernandez, D., & Chen, L. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1140030 · Cited by 10
Bauer, S. L., Comer, H., Ramsey, B., & Thomas, K. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.5.7 · Cited by 12
“…been reported with nilotinib in retrospective and prospective studies at a frequency of 1.1% to 16.7% (Aichberger et al., 2011; Giles et al., 2013; Larson et al., 2012; Le Coutre et al., 2011; Quintas-Cardama et al., 2012; Novartis Pharmaceuticals, Inc., 2018b); when the ankle–brachial index is…”
BackgroundInfluentialPaul, T., Ellahie, A. Y., Almohtasib, Y. S., Sinha, U., & Omri, H. E. (2021) · eJHaem · doi:10.1002/jha2.226 · Cited by 10
Giona, F., Malaspina, F., Putti, M. C., Ladogana, S., Mura, R., Burnelli, R., Vacca, N., Rizzo, L., Bianchi, S., Moleti, M. L., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16388 · Cited by 9
“The alternative schedules of intermittent TKI, as used in the elderly population (Faber et al., 2006; Shah et al., 2008; Russo et al., 2013; La Rosee et al., 2013; Malagola et al., 2019), were discarded due to parents’ concerns about leaving their children without therapy for longer periods.”
BackgroundA safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
Özmen, D., Alpaydin, D. D., Saldoğan, M. A., & Eşkazan, A. E. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2331190 · Cited by 9
“Besides dose reduction, an on/off treatment with a weekend holiday may be an alternative [28,29].”
BackgroundKazantsev, I. V., Gevorgyan, A. G., Yukhta, T. V., Tolkunova, P. S., Zvyagintseva, D. A., Козлов, А. В., Голенкова, М. С., Бабенко, Е. В., Kuga, P. S., Shvetsov, A. N., et al. (2020) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2020-19-2-129-140 · Cited by 5
[Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].
(2025) · PubMed Central · doi:10.3760/cma.j.cn121090-20250923-00437 · Cited by 6
Managing Pregnancy in Chronic Myeloid Leukemia
Palani, R., Milojković, D., & Apperley, J. F. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_11 · Cited by 4
Werk, R. S., Mehrhoff, C. J., & Badawy, S. M. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31686 · Cited by 3
Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Chen, J., Zhu, Y., Zhao, Y., Guo, N., Yao, Y., Luo, X., & Huang, L. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s532263 · Cited by 5
Chronische myeloische Leukämie
Ernst, T., Obstfelder, E., & Hochhaus, A. (2018) · Der Onkologe · doi:10.1007/s00761-018-0380-5 · Cited by 3
Self-citationMolecular-Targeted Therapy in Refractory or Relapsed Neuroblastoma
Corbacioglu, S. (2015) · Pediatric and adolescent medicine · doi:10.1159/000382098 · Cited by 3
Chronische myeloische Leukämie
Hochhaus, A., Rosée, P. G. L., Eigendorff, E., & Ernst, T. (2015) · Der Internist · doi:10.1007/s00108-014-3594-7 · Cited by 3
Self-citationGurianova, M. A., Kazey, V. I., Shukhov, O. A., Chelysheva, E., Никифорова, А. Г., Соболев, П. Д., Dolov, M. S., Grebenkin, D. Y., Петрова, А. Н., Быкова, А. В., et al. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-4-347-359 · Cited by 1
Žáčková, D. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.073 · Cited by 1
Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors
Gurianova, M. A., Chelysheva, E., & Turkina, A. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-1-118-128 · Cited by 1
“Важно отметить, что у 58 % больных отмечалось углубление ответа после перехода на прерывистый режим терапии [39].”
Chronische myeloische Leukämie — State of the Art
Hochhaus, A., Eigendorff, E., Fabisch, C., & Ernst, T. (2016) · best practice onkologie · doi:10.1007/s11654-016-0589-y
Self-citationModernes Management der chronischen myeloischen Leukämie*
Ernst, T., Obstfelder, E., & Hochhaus, A. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-3607-9
“Es gibt Hinweise auf eine Senkung der Rate an Nebenwirkungen durch eine Wochenendpause der DasatinibBehandlung (5-mal 100 mg/Woche), die aufgrund der kurzen Halbwertszeit des Medikaments möglich und eektiv ist [8].”
BackgroundSelf-citationPleurotoxic Drugs—an Update: Someone Else to Blame?
Skouras, V. S., & Kalomenidis, I. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-0225-8
Dasatinib/imatinib: Various toxicities: 33 case reports
(2013) · Reactions Weekly · doi:10.1007/s40278-013-7023-9
Crysandt, M. M., & Brümmendorf, T. H. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1941-7438
Metadata
- Authors
- La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A.
- Affiliations
- Institut Jules Bordet (BE)
- Heidelberg University (DE)
- Jena University Hospital (DE)
- Venue
- Annals of Hematology
- Published
- 2013-04-28
- Volume
- 92
- Issue
- 10
- Pages
- 1345-1350
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W2003589239
- Cited by
- 50
- References
- 27
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 1 · 2016: 6 · 2015: 5 · 2014: 3 · 2013: 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Annals of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, chronic myeloid leukemia, intermittent dosing, imatinib resistance, imatinib intolerance, dose reduction, pleural effusion, hematologic toxicity, fluid retention, off-target toxicity, treatment tolerability
- MeSH terms
- Imatinib Mesylate, Dasatinib, Adult, Aged, Aged, 80 and over, Benzamides, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Piperazines, Pyrimidines, Retrospective Studies, Thiazoles, Leukemia, Myeloid, Chronic-Phase, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.